Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (228)

« Back to Publications

Studying Early Life Live-Attenuated influenza virus immune Responses (STELLAR): study protocol for an exploratory observational study of the nasal mucosal and systemic immune response in healthy children given an intranasal live-attenuated influenza vaccine.

Kelleher K. et al, (2026), BMJ Open, 16

Delivery of multiple PspA fragments by CyaA toxoid induces broad protection against Streptococcus pneumoniae

Carneiro GB. et al, (2026)

Host-microbial interactions at the nasal mucosa in young children and adults: A retrospective, cross-sectional study.

Reiné J. et al, (2026), Cell Rep, 45

Effect of 13-valent pneumococcal conjugate vaccine on experimental carriage at 1-year post-vaccination on rechallenge with Streptococcus pneumoniae serotype 6B in Blantyre, Malawi: a controlled human infection study and longitudinal follow-up of a randomised controlled trial.

Chirwa AE. et al, (2026), Lancet Microbe, 7

Disease-Attenuated Pneumococcal Biosynthesis Gene Mutants Invade the Mucosal Epithelium and Induce Innate Immunity.

Weight CM. et al, (2026), J Infect Dis

13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.

Tembo G. et al, (2026), Vaccine, 75

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies.

Cheliotis KS. et al, (2026), Vaccine, 75

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.

Liatsikos K. et al, (2026), Lancet Microbe, 7

Controlled human pneumococcal infection in the Netherlands: Colonisation, antibody responses and the impact of viral co-infection.

van Beek LF. et al, (2026), J Infect, 92

Pneumococcal colonisation and mucosal immunity in adults with asthma following experimental human challenge

Reiné J. et al, (2026), BMJ Immunology, 1, e000012 - e000012

Pooled analysis of PCV13 efficacy from controlled human infection trials in Malawi and the UK.

Kudowa E. et al, (2026), NPJ Vaccines

Correction: Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.

Mamede I. et al, (2026), Front Immunol, 17

Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review.

Hamilton DO. et al, (2026), PLoS Negl Trop Dis, 20

Persistent pneumococcal colonisation in antiretroviral-treated HIV infection is associated with nasal inflammation.

Phiri JA. et al, (2025), Nat Commun, 17

Systematic review of antimycobacterial therapy for Bacille Calmette-Guérin infection in hosts without significant immunocompromise.

Carter EC. et al, (2025), Int J Infect Dis, 161

Load More

1
2
3
4
5
6
7
...
»